1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Mega-Rounds Around The World As VCs Spread The Wealth

China-Based Vector Supplier Raised $40m Series B+

 
• By Mandy Jackson

Private Company Edition: After US-based Alumis and Sionna raised $259m and $182m, respectively, in series C rounds, Tubulis in Munich, Germany brought in €128m ($138.8m) in series B2 cash, while Rakuten – with offices in the US, Europe and Asia – closed a $119m series E round.

Finance Watch Private Company
• Source: Shutterstock

Recent biopharmaceutical venture capital financings reflect a worldly investment view, even at the $100m-plus mega-round level where the largest investments tend to be more frequent in the US. The six mega-rounds during the first half of March included a German antibody-drug conjugate (ADC) developer and a cell therapy firm with operations in the US, Europe and Asia.

South San Francisco-based Alumis, Inc. topped the list with a $259m series C round, followed by Sionna Therapeutics, Inc. in Boston with a $182m series C, a $145m series E for FogPharma in Cambridge, MA, Munich, Germany-based Tubulis GmbH’s €128m ($138.8m) series B2, a $100m series B round for BlossomHill Therapeutics, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.